Analysis of the Impact of Helicobacter Pylori on Salivary Microbiome in Adults

Shanghai Jiao Tong University School of Medicine60 enrolled

Overview

Helicobacter pylori (H. pylori), a bacteria transmitted from human to human through upper digestive tract as well as fecal-oral transmission, had infected more than half of people around the world. However, the quantity of H. pylori in oral cavity and its influence on oral microbiota remains to be unclear. The aim of the present study was to examine the effects of H. pylori infection as well as its eradication on oral microbiota.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Helicobacter Pylori Infection

Interventions

EsomeprazoleDRUG

Proton pump inhibitor

AmoxicillinDRUG

Antibiotics for H. pylori eradication

Bismuth Potassium CitrateDRUG

Gastric mucosal protective drug with anti-H. pylori effect

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants with non-ulcer functional dyspepsia or peptic ulcer disease * Ability and willingness to participate in the study and to sign and give informed consent * Received both endoscopy and 13C urea breath test (13C-UBT) before enrolled Exclusion Criteria: * Less than 18 years old * With previous gastric surgery * Major systemic diseases * Pregnancy or lactation * Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion * The use of antibiotics or PPI within 2 months before the study * The presence of dental carious or any untreated cavitated carious lesions and oral abscesses

Locations (1)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Change of saliva microbiota after eradication

Two months after completion of therapy, saliva microbiota was assessed by 16S rDNA Pyrosequencing.

Time frame: Two months after completion of therapy.

Central Contacts

Yingjie Ji, M.D.

CONTACT

86+15800575527 jiyingjie39@outlook.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.